Publications by authors named "Sunfa Cheng"

Claim this Profile
P
Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel.
David E Henner, Beatrice Drambarean, Teresa M Gerbeling, Jessica B Kendrick, William T Kendrick, Sunfa Cheng

PLoS One· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel.
David E Henner, Beatrice Drambarean, Teresa M Gerbeling, Jessica B Kendrick, William T Kendrick, Sunfa Cheng

PLoS One· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.
Koichi Hirata, Takao Takeshima, Fumihiko Sakai, Yotaro Numachi, Ryuji Yoshida, Sunfa Cheng

BMJ Open· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Stewart J Tepper, Richard B Lipton, Stephen D Silberstein, David Kudrow, Messoud Ashina, Sunfa Cheng

Headache· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness.
Angelo Karaboyas, Daniel Muenz, Yunji Hwang, William Goodman, Sunfa Cheng

Kidney Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Messoud Ashina, Stewart J Tepper, Jan Lewis Brandes, Uwe Reuter, Guy P Boudreau, Sunfa Cheng

Headache· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.
John Mark Stephens, Kathleen M Fox, Pooja Desai, Sunfa Cheng, William G Goodman

Hemodial Int· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
Koichi Hirata, Takao Takeshima, Fumihiko Sakai, Noboru Imai, Yasuhiko Matsumori, Cheng Peng, Sunfa Cheng

Brain Behav· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis.
Changying Xing, Jing Chen, Li Zuo, Yi Fang, Xiaoqiang Ding, Sunfa Cheng

Clin Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia.
Richard B Lipton, Rami Burstein, Dawn C Buse, David W Dodick, Reija Koukakis, Sunfa Cheng

Cephalalgia· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.
Koichi Hirata, Fumihiko Sakai, Takao Takeshima, Noboru Imai, Yasuhiko Matsumori, Cheng Peng, Sunfa Cheng

J Headache Pain· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Stewart J Tepper, Messoud Ashina, Uwe Reuter, Yngve Hallström, Gregor Broessner, Sunfa Cheng

J Headache Pain· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takao Takeshima, Fumihiko Sakai, Koichi Hirata, Noboru Imai, Yasuhiko Matsumori, Cheng Peng, Sunfa Cheng

Headache· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial.
Messoud Ashina, Peter J Goadsby, Uwe Reuter, Stephen Silberstein, David W Dodick, Sunfa Cheng

Eur J Neurol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Fumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, Koichi Hirata, Sunfa Cheng, Cheng Peng

Headache· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
Richard B Lipton, Stewart J Tepper, Stephen D Silberstein, David Kudrow, Messoud Ashina, Sunfa Cheng

Cephalalgia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
David A Bushinsky, Glenn M Chertow, Sunfa Cheng, Hongjie Deng, Nelson Kopyt

Nephrol Dial Transplant· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum.
David A Bushinsky, Glenn M Chertow, Sunfa Cheng, Hongjie Deng, Nelson Kopyt

Nephrol Dial Transplant· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Stewart J Tepper, Messoud Ashina, Uwe Reuter, Jan Lewis Brandes, David Doležil, Sunfa Cheng

Cephalalgia· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular safety of erenumab for migraine prevention.
David Kudrow, Julio Pascual, Paul K Winner, David W Dodick, Stewart J Tepper, Sunfa Cheng

Neurology· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
Jan Lewis Brandes, Hans-Christoph Diener, David Dolezil, Marshall C Freeman, Peter J McAllister, Sunfa Cheng

Cephalalgia· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Fumihiko Sakai, Takao Takeshima, Yoshihisa Tatsuoka, Koichi Hirata, Robert Lenz, Sunfa Cheng

Headache· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
Messoud Ashina, Peter J Goadsby, Uwe Reuter, Stephen Silberstein, David Dodick, Sunfa Cheng

Cephalalgia· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
Stewart J Tepper, Hans-Christoph Diener, Messoud Ashina, Jan Lewis Brandes, Deborah I Friedman, Sunfa Cheng

Neurology· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Richard B Lipton, Stewart J Tepper, Uwe Reuter, Stephen Silberstein, Walter F Stewart, Sunfa Cheng

Neurology· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis